Wai Chun Bio-Technology (HKG:0660) expects a net loss of up to HK$13 million for the year ended June 30, down from HK$65.7 million a year prior, a Friday Hong Kong bourse filing said.
The biochemical products maker attributed the forecast to a decline in impairment losses on non-financial assets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.